Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cellectar Biosciences

0.3771
+0.040311.97%
Post-market: 0.38500.0079+2.09%17:09 EDT
Volume:2.56M
Turnover:946.46K
Market Cap:17.38M
PE:-0.27
High:0.3917
Open:0.3420
Low:0.3369
Close:0.3368
Loading ...

Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?

Zacks
·
Yesterday

Cellectar Biosciences Enhances CEO and COO Severance Benefits

TIPRANKS
·
Yesterday

Cellectar Biosciences: Promising Future with FDA Clarity and Innovative Radiopharmaceutical Advancements

TIPRANKS
·
15 Mar

Oppenheimer Keeps Their Hold Rating on Cellectar Biosciences (CLRB)

TIPRANKS
·
14 Mar

Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ...

GuruFocus.com
·
14 Mar

Cellectar Biosciences Faces Financial and Legal Turmoil Amidst Restated Earnings

TIPRANKS
·
14 Mar

Cellectar Biosciences Advances Cancer Drug Pipeline

TIPRANKS
·
14 Mar

Q4 2024 Cellectar Biosciences Inc Earnings Call

Thomson Reuters StreetEvents
·
14 Mar

Cellectar Biosciences Earnings Call: Mixed Outlook Amid Successes and Challenges

TIPRANKS
·
14 Mar

Cellectar Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Mar

Cellectar Biosciences reports FY24 EPS ($1.40), consensus ($1.57)

TIPRANKS
·
13 Mar

Cellectar Biosciences sees cash runway into 4Q25

TIPRANKS
·
13 Mar

Cellectar Biosciences Says Its Cash Balance Of $23.3M As Of December 31, 2024, Is Adequate To Fund Its Basic Budgeted Operations Into The Fourth Quarter Of 2025

Benzinga
·
13 Mar

Press Release: Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Dow Jones
·
13 Mar

Cellectar Biosciences FY 2024 GAAP EPS $(1.40) Beats $(1.59) Estimate

Benzinga
·
13 Mar

Cellectar Biosciences to Present at the 37th Annual Roth Conference

GlobeNewswire
·
11 Mar